Form 4: Niagen Bioscience Director Steven Rubin Granted 20,000 Stock Options

Steven D. Rubin, a Director and 10% Owner of Niagen Bioscience, Inc., was granted 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Summary

• Steven D. Rubin, identified as a Director and 10% Owner of Niagen Bioscience, Inc. (NAGE), was granted 20,000 stock options.
• The stock options have an exercise price of $14.13 per share.
• These options are scheduled to vest 100% on June 24, 2026.
• The expiration date for the granted stock options is June 23, 2035.
• Following this transaction, Mr. Rubin directly beneficially owns 20,000 derivative securities, specifically stock options.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice that aligns the director's interests with the company's long-term performance, generally viewed as a positive for corporate governance and incentive structure.

Positives

• The grant of 20,000 stock options to Director Steven D. Rubin aligns his financial interests with the long-term performance and shareholder value of Niagen Bioscience, Inc.

Future Outlook

The stock options granted to Director Steven D. Rubin are set to vest 100% on June 24, 2026, indicating a future incentive structure designed to align his long-term commitment with the company's performance.

Industry Context

This Form 4 filing is a routine disclosure for insider transactions within publicly traded companies, reflecting a common practice of granting equity incentives to directors and executives to align their interests with the company's long-term performance and shareholder value.

Related Party Transactions

• The grant of 20,000 stock options to Steven D. Rubin, a Director and 10% Owner, constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Steven D. Rubin will be able to exercise the granted stock options starting June 24, 2026, upon their full vesting.

Key Dates

Keywords

Niagen Bioscience, NAGE, Steven D. Rubin, stock options, insider transaction, Form 4, director compensation, equity grant